MOFFITT 2019 INNOVATION INDEX

- **56** original U.S. patent applications
- **213** worldwide patent applications
- **11** active startups
- **56** licenses
- **12** intellectual property disclosures
- **59** U.S. patents issued
- **$36 MILLION** global funding

**FY2019 OFFICE OF INNOVATION AND INDUSTRY ALLIANCES**
# AGENDA

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 – 9:15am</td>
<td>BREAKFAST AND NETWORKING</td>
<td>RICHARD O. JACOBSON ATRIUM</td>
</tr>
<tr>
<td>9:15 – 11:00am</td>
<td>WELCOME AND KEYNOTE ADDRESS</td>
<td>COUCH AUDITORIUM</td>
</tr>
<tr>
<td></td>
<td>• Dr. Alice Jacobs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Physician, Entrepreneur, Inventor and Investor is interviewed by</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Charles Gibson, internationally renowned journalist and former anchor of ABC’s World News with Charles Gibson and host of Good Morning America</td>
<td></td>
</tr>
<tr>
<td>11:30am – 12:30pm</td>
<td>BREAKOUT SESSIONS</td>
<td>COUCH AUDITORIUM</td>
</tr>
<tr>
<td></td>
<td>• AI: Navigating the Digital Health Super Highway</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: Dr. Ross Mitchell, Moffitt Cancer Center</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Baby You Can Drive My CAR(T): Future Challenges with Cell Therapy and Manufacturing</td>
<td>FERMAN CONFERENCE ROOM</td>
</tr>
<tr>
<td></td>
<td>Moderator: Dr. Adam Mailloux, Moffitt Cancer Center</td>
<td></td>
</tr>
<tr>
<td>12:30 – 2:00pm</td>
<td>LUNCH AND NETWORKING</td>
<td>RICHARD O. JACOBSON ATRIUM</td>
</tr>
<tr>
<td>1:15 – 1:45pm</td>
<td>TOURS</td>
<td></td>
</tr>
<tr>
<td>2:00 – 3:00pm</td>
<td>BREAKOUT SESSIONS</td>
<td>COUCH AUDITORIUM</td>
</tr>
<tr>
<td></td>
<td>• Driving Your Funds to the Finish Line:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>VCs and Entrepreneurs Reveal What Counts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: Todd Creech, HealthQuest Capital</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• The Immunotherapy Race: Putting Your Immune System in Drive</td>
<td>FERMAN CONFERENCE ROOM</td>
</tr>
<tr>
<td></td>
<td>Moderator: Dr. Brian Ruffell, Moffitt Cancer Center</td>
<td></td>
</tr>
<tr>
<td>OPEN ALL DAY</td>
<td>BRAKE &amp; REFUEL</td>
<td>MURPHEY CONFERENCE ROOM</td>
</tr>
<tr>
<td></td>
<td>Network, charge your device and refuel</td>
<td></td>
</tr>
</tbody>
</table>

**Moderator:**
- Dr. Ross Mitchell, Moffitt Cancer Center
- Dr. Adam Mailloux, Moffitt Cancer Center
- Todd Creech, HealthQuest Capital
- Dr. Brian Ruffell, Moffitt Cancer Center
- Charles Gibson, internationally renowned journalist and former anchor of ABC’s World News with Charles Gibson and host of Good Morning America
Based at Caltech - convening Nobel laureates and National Academy members to build the next generation of health and other deep technology solutions. These are foundational achievements with the potential to change the world. In this capacity Dr. Jacobs has become an advisor globally to technologists, startups, major companies, governments and investors.

Dr. Jacobs performed her first scientific experiments at 16 with Dr. Irving Weissman (discoverer of the stem cell) at Stanford and was then published in the field of developmental neurobiology at 19. Her independent research in neuroscience resulted in a paradigm shift in understanding the development of the cerebral cortex. While at Harvard Medical School, Dr. Jacobs cofounded a health technology receiving funding from both Bill Gates and Jeff Bezos. As Chair and CEO, she successfully brought multiple products through the FDA and onto five continents.

Dr. Jacobs has served as an advisor to Fortune 100 Companies as well as Third Rock Ventures/MIT/Bob Langer, GE Ventures, FiNC Technologies, GreyBird Ventures and Essex Management—a Jacobs family investment vehicle. Advisory/investor roles including health/wellness, artificial intelligence/machine learning/computer vision/data analytics-driven applications, biotech, microbiome, genomics, neuroscience, synthetic biology and robotics/autonomous systems, cybersecurity, and sustainability.

Dr. Jacobs holds multiple patents and has been recognized by Scientific American as one of the top 50 innovators and by the World Economic Forum as a Young Global Leader, a 40 under 40 award by the Boston Business Journal as well as for Healthcare Innovation in Clinical Diagnostics by Frost & Sullivan. She holds a BA in Art History, a BS in Biological Sciences from Stanford with Honors in Developmental Neurobiology and an MD from Harvard Medical School.
Charles Gibson
Award Winning Journalist and Broadcaster
Retired ABC News Anchor

Charlie Gibson is a legendary American broadcast television anchor and journalist with more than 40 years of experience reporting from all over the globe. Mr. Gibson is a graduate of Princeton University, where he served as the news director for the University’s radio station. Following a short stint in the US Coast Guard, he was hired as a producer, reporter and later an anchor for the local television network in Lynchburg, Virginia. In 1970, he moved to Washington DC where he served as an anchor for the local ABC network affiliate. Shortly after this role, Charlie joined the syndicated news service Television News, Inc (TVN). While at TVN, he covered the Watergate scandal investigations and subsequent resignation of President Richard Nixon.

His career with ABC News started in 1975 after his role with TVN. At ABC news Charlie reported on a wide array of national stories including investigations of government agencies, economic developments, Gerald Ford’s presidential campaign and Ronald Reagan's legislative agenda. He served as chief correspondent at the House of Representatives for ABC News from 1981 to 1987. Many may remember Mr. Gibson as a popular anchor of the show “Good Morning America” from 1987 to 2006. During his tenure on “Good Morning America”, Mr. Gibson covered many key events that shaped our world including terrorist attacks, presidential campaigns and debates, as well as election of a new Pope. Mr. Gibson also interviewed leaders from around the world. From 1985 to 1995, “Good Morning America” was the most-watched morning show on American television.

Following “Good Morning America”, Gibson served as anchor for “World News with Charlie Gibson” from 2005 until his retirement in 2009. For his work in journalism, Charlie Gibson has been awarded several honorary doctorate degrees, multiple Emmy awards, the Paul White Award from the Radio Television Digital News Association, and the Fred Friendly First Amendment Award from Quinnipiac University.
AI: NAVIGATING THE DIGITAL HEALTH SUPER HIGHWAY
11:30 a.m. - 12:30 p.m. - Ted and Marty Couch Auditorium

MODERATOR

Ross Mitchell, PhD
Moffitt Cancer Center
Artificial Intelligence Officer
Senior Member, Department of Biostatistics and Bioinformatics

J. Ross Mitchell, PhD, is the Artificial Intelligence Officer, and a Senior Member of the Research Staff at Moffitt Cancer Center. He moved from Mayo Clinic Arizona in 2019 to become Moffitt’s inaugural Artificial Intelligence Officer. In this role he leads efforts to develop digital tools that utilize artificial intelligence and other advanced technologies to improve the efficiency and quality of cancer care. Dr. Mitchell is also a Senior Member of Moffitt’s Department of Biostatistics and Bioinformatics, and collaborates with fellow research faculty to optimize projects utilizing artificial intelligence applications. He is one of four Principal Investigators of a $3.6 million grant from the U.S. National Cancer Institute, designed to unravel the connections between medical imaging, genomics and disease progression in brain cancer. Dr. Mitchell has BS and MS degrees in Computer Science from the University of Regina, and a PhD in Medical Biophysics from the University of Western Ontario.

PANELISTS

Alice Jacobs, MD
Physician, Entrepreneur,
Investor and Inventor

Shez Partovi, MD
Life Sciences, Genomics,
Medical Devices, AgTech
Amazon Web Services

Based at Caltech - convening Nobel laureates and National Academy members to build the next generation of health and other deep technology solutions, Dr. Jacobs has become an advisor globally to technologists, startups, major companies, governments, and investors. Advisory and investor interests include but are not limited to artificial intelligence and machine learning as well as data analytics and computer vision-driven applications. She holds a BA in Art History, a BS in Biological Sciences from Stanford with Honors in Developmental Neurobiology and an MD from Harvard Medical School. While at Harvard Medical School, Dr. Jacobs co-founded a health technology receiving funding from both Bill Gates and Jeff Bezos. As Chair and CEO, she successfully brought multiple products through the FDA and onto five continents. Dr. Jacobs holds multiple patents and has been recognized countless times by top tier scientific and media outlets.

Dr. Shez Partovi obtained his medical degree from McGill University, in Montreal, Canada and completed his neuroradiology subspecialty training at Barrow Neurological Institute in Phoenix, AZ. He is a serial entrepreneur and has launched a number of health IT companies, one of which was a telehealth company built on AWS. After a decade of clinical practice, Dr. Partovi transitioned to Dignity Health where he served as Chief Health Information Officer and Chief Digital Officer/SVP of Digital Transformation. In these roles, Dr. Partovi oversaw the deployment of Cerner and he was responsible for the digital experience of consumers, patients, and providers enterprisewide. Shez joined Amazon Web Services in 2018 as the Worldwide lead for Healthcare, Life Sciences and Genomics. He is currently working on over a dozen large scale initiatives across the globe and has a unique perspective of the opportunities to transform healthcare worldwide.
Dr. Randa Perkins is the Chief Medical Information Officer (CMIO) at Moffitt Cancer Center. As CMIO, she is responsible for contributing to the long-term vision of IT health systems at Moffitt, and the Clinical Informatics Department, which facilitates both implementation and optimization of the electronic health record (EHR) and its various uses. Dr. Perkins is a former computer programmer who earned her medical degree from the Florida State University College of Medicine. Her background in programming has led to the discovery of processes combining IT and medicine for better EHR utilization for physicians. She completed her residency at the Tallahassee Memorial Family Medicine Residency Program, serving as chief resident. Prior to joining Moffitt, she was Tallahassee Memorial HealthCare’s Executive Director of Medical Informatics. Dr. Perkins continues her clinical practice as well, seeing patients in Moffitt’s Ambulatory Internal Medicine clinic, providing direct medical care for Moffitt patients.

Dr. Tyler Wagner is the Head of Biomedical Research at nference, a startup developing an AI software platform for real-time, automated extraction of knowledge from scientific, clinical, regulatory and commercial datasets. Prior to joining nference, Dr. Wagner obtained his PhD in the Weiss lab (MIT) and Densmore lab (BU) where he engineered an RNA virus into a multi-functional platform for regulated gene delivery. He continued with a postdoc in the Weiss lab where he explored \textit{in vivo} regulatory strategies for self-amplifying RNA therapeutics. At nference, he is currently leading research projects with aims ranging from target identification to label expansion, and is working to apply machine learning to outstanding questions in multiple therapeutic areas, including cardiology, metabolism, and neuroscience.
BABY YOU CAN DRIVE MY CAR(T): FUTURE CHALLENGES WITH CELL THERAPY AND MANUFACTURING

11:30 a.m. - 12:30 p.m. - Ferman Family Conference Room

MODERATOR

Adam Mailloux, PhD
Assistant Member
Immunology Department
Assistant Director, Cell Therapies Facility
Moffitt Cancer Center

Dr. Mailloux is an Assistant Member in the Department of Immunology. Prior to joining the faculty, Dr. Mailloux served as postdoctoral fellow and research scientist at Moffitt where he explored the pathophysiology of hematopoietic disease in the context of immune homeostasis as well as the development of novel methods to isolate and expand tumor-reactive infiltrating lymphocytes for therapeutic use. His current research interests focus on the design and implementation of novel approaches to boost the effectiveness of anti-cancer immunotherapies. His research programs complement the strengths of the Immunology Program and ensure the successful evolution of our state-of-the-art Cell Therapy Facility, where he also serves as the Assistant Technical Director. Adam received his bachelor’s degrees in chemistry and biochemistry from the University of Charleston and his PhD in microbiology and immunology from the Medical University of South Carolina.

PANELISTS

Cécile Chartier, PhD
Vice President, Research
Iovance Biotherapeutics

Cécile Chartier, Ph.D. is currently serving as Vice President of Research at Iovance Biotherapeutics. She led OncoMed Pharmaceuticals’ Target Validation group from 2005 to 2017, as a Senior Director. From 2001 to 2004, Dr. Chartier was a Scientist III in Berlex Biosciences’ Gene Therapy department. Her career as a scientist started at the French Biotechnology company Transgene. Dr. Chartier is a Molecular Biologist by training. She obtained her Bachelor’s, Master’s, and Ph.D. in 1987, 1988, and 1993 from the Université Louis Pasteur of Strasbourg, France. She pursued post-doctoral training at Harvard Medical School in Boston from 1997 to 2000, followed by one year at Stanford University in 2001.

William Go, MD, PhD
Sr. Vice President & Head of Development
A2 Biotherapeutics

As Senior Vice President and Head of Development at A2 Biotherapeutics, Will’s organization oversees process development through to clinical development, utilizing A2’s novel platform technology to develop immunocellular therapy in serious diseases including cancer. Prior to A2 Bio, Will worked at Kite Pharma, where he led the ZUMA-1 pivotal study and FDA approvals of YESCARTA®. Prior to Kite Pharma, Will worked at Amgen where he played an instrumental role in the clinical development of Vectibix® in colorectal cancer as well as identifying new predictive biomarkers, as a Medical Director in Global Clinical Development. Will received his BA in Biology from Carleton College and then his PhD as well as MD from the University of California San Diego. He also completed his internal medicine residency, hematology/oncology fellowship at UCSD.
TJ Langer has a background in biomedical engineering and has been in the industry for 15 years. As one of the early employees at Kite Pharma, he worked to develop the successful, FDA-approved YESCARTA® CAR-T product from pre-IND to BLA approval. After the Gilead acquisition, he led the development of engineered T cell products targeting neoantigens. His new biotechnology company, Myst Therapeutics, aims to make cancer cell therapy for solid tumors more effective and accessible to patients.

Paul Stead is Vice President of Business Development at Adaptimmune Therapeutics. Adaptimmune is a leader in the discovery and development of TCR T-cell therapies for treatment of solid tumors. Prior to joining Adaptimmune, Paul worked in senior business development roles at Inovio Pharmaceuticals, Nimbus Therapeutics, and GlaxoSmithKline. Paul obtained a Bachelor of Pharmacy degree from the University of Bath, UK, and holds a PhD (University of Nottingham, UK) and an MBA (Lehigh University, Bethlehem, PA).

Dr. José Eduardo Vidal joined Atara Biotherapeutics in 2018. Prior to Atara, Dr. Vidal served as Vice President, Drug Substance Operations at Amgen managing a $500 million budget across their global drug substance manufacturing network. He was also Amgen’s Executive Director, Process Development, where he collaborated closely with manufacturing and quality to accelerate the delivery of a product portfolio comprised of over ten Phase 3 products. José also held several senior roles at Pfizer, as well as Wyeth and Biovail with a focus on global manufacturing and quality operations. José received his bachelor’s degree in molecular biology, master’s degree in molecular endocrinology and biochemistry and PhD in biochemistry and cellular molecular biology all from the University of Puerto Rico, Rio Piedras.
Todd Creech is a partner at HealthQuest Capital, a growth equity, private equity firm investing in commercial-stage companies across the healthcare industry. Over the last 10 years, Todd has served as a healthcare CFO, helping build several successful companies to profitable exits. He joined HealthQuest in 2016 to bring his operations and financial experiences to innovative companies that are primed for growth with the right plan and execution. He currently serves as board member of HealthQuest portfolio companies Alcresta, BioIQ, and Etairos and an observer for HealthChannels, Springbuk, InMediata, Avedro, and Venus Concept. During his CFO tenure, he has raised more than $500M in equity and debt, helping to build operations and companies that generated over $3.5B in exits. Todd holds bachelor's degrees in Finance and Accounting from Miami (Ohio) University and an MBA from Duke University.

PANELISTS

James Bianco, MD
Founder and Executive Chairman
TuHURA BioPharma, Inc.

Benjamin Chen, PhD
Venture Partner
Panacea Venture

Dr. Bianco is the principle founder and Executive Chairman of TuHURA BioPharma, an immuno-oncology start up spun out of the Moffitt Cancer Research Center. He also serves as Chief Development Officer at Drais Pharmaceuticals focusing on identifying, acquiring or licensing novel drug candidates for new start-ups. Previously, he served as the principal founder and CEO of CTI Biopharma for 24 years, leading the company to the commercial launch of 3 novel therapeutics. Dr. Bianco earned his M.D. from the Mount Sinai Icahn School of Medicine and completed his residency at the Mount Sinai Medical Center in NYC. He completed his fellowship in Hematology/Oncology at the University of Washington/Fred Hutchinson Cancer Research Center (FHCRC) where he was a member of the faculty and Director of the Bone Marrow Transplant Unit. He is an inventor on 16 issued patents.

Dr. Benjamin Chen is a Venture Partner with Panacea Venture, a global life science venture fund. Most recently, Benjamin served as the CEO of ImaginAb, Inc., a company developing a cutting edge platform to address an urgent unmet need in immuno-oncology. Immediately before that, he was the Chairman and CEO of London based Immune Targeting Systems, leading the immune therapy company through significant strategic growth, innovative product development and establishing a presence in France and North America. Prior to returning to operational roles, he spent nine years as a Managing Director at Burrill & Company, a global life sciences venture firm where he evaluated investment opportunities, assisted a global clientele in completing licensing, partnering and M&A transactions. Dr. Chen received his academic training in Microbiology and Immunology at the University of Wisconsin-Madison and Stanford University.
LINE: VCs AND ENTREPRENEURS

Geoffrey Duyk, MD, PhD
Founder and Managing Partner
Circularis Partners

Dr. Duyk is Founder and Managing Partner of Circularis Partners, a group focused on supporting technology-enabled companies that advance the circular economy and promote sustainability as well as resource efficiency. Prior to Circularis, Dr. Duyk was the Managing Director and Partner of TPG Alternative & Renewable Technologies/TPG Biotechnology. Dr. Duyk has also held several executive roles in industry research and development. Prior to industry, Dr. Duyk was an Assistant Professor at Harvard Medical School in the Department of Genetics and an Assistant Investigator of the Howard Hughes Medical Institute. Dr. Duyk holds an MD and PhD from Case Western Reserve University. He completed his medical and fellowship training at the University of California, San Francisco. While at UCSF, Dr. Duyk was a fellow of the Lucille P. Markey Foundation and was awarded a post-doctoral fellowship from HHMI.

Myla Lai-Goldman, MD
Founder and Executive Chairperson
GeneCentric Therapeutics

Dr. Lai-Goldman is Co-Founder and Executive Chairperson of GeneCentric Therapeutics. She served as CEO and president from 2011 through 2018. Dr. Lai-Goldman spent more than 18 years at Laboratory Corporation of America (LabCorp), the last 10 years as Executive Vice President, Chief Medical Officer and Chief Scientific Officer. During her tenure at the company, she led all clinical, scientific and medical activities, including the introduction of more than 400 clinical assays. Her experience includes the development of partnerships, licensing, and acquisitions. After leaving LabCorp, Dr. Lai-Goldman became a Venture Partner at Hatteras Venture Partners and is the managing partner of Personalized Science, a consulting company founded to assist customers achieve successful adoption of innovative diagnostics. Dr. Lai-Goldman received her BS from the University of Pennsylvania and MD from Columbia University. Dr. Lai-Goldman is board-certified in anatomic and clinical pathology.

Michael Luther, PhD
President and CEO
Teewinot Life Sciences Corp.

Dr. Luther is currently the CEO of Teewinot Life Sciences, a global leader in the development and production of cannabinoids and their derivatives for consumer and pharmaceutical markets. Previous roles include the Vice President and Head of R&D for Merck-Canada leading Merck’s global discovery efforts in inflammation and metabolic disease, as well multiple roles with GlaxoSmithKline including Vice President in Discovery Research. At GSK, he led multiple teams that led to the successful launch of new therapeutics in oncology and metabolic disease. Dr. Luther holds Bachelor of Science degrees from North Carolina State University, a PhD from the St. Louis University School of Medicine, and an MBA from Duke University. He is the author of over 65 publications and holds issued patents in diagnostics and pharmaceuticals.
THE IMMUNOTHERAPY RACE: PUTTING YOUR IMMUNE SYSTEM IN DRIVE
2:00 p.m. - 3:00 p.m. - Ferman Family Conference Room

MODERATOR
Brian Ruffell, PhD
Assistant Member
Immunology Department
Moffitt Cancer Center

Brian Ruffell, PhD received his doctorate in Immunology at the University of British Columbia, completed postdoctoral studies in Cancer Immunology at the University of California, San Francisco and Oregon Health and Science University, and joined the faculty at the Moffitt Cancer Center and Research Institute in Tampa, Florida in 2015. The Ruffell lab is focused on discovering how macrophages and dendritic cells regulate the efficacy of standard-of-care therapeutics, especially in poorly immunogenic, hormone-driven malignancies, with the ultimate goal of targeting these cells to enhance anti-tumor immunity.

PANELISTS
Mark Cantwell, PhD
Chief Scientific Officer
Memgen

Mark Cantwell, PhD is the Chief Scientific Officer of Memgen, LLC. In this role, he is responsible for the development of Memgen’s cancer immunotherapy pipeline, including its lead drug product MEM-288, a powerful new oncolytic adenovirus developed in collaboration with scientists at Moffitt Cancer Center. Dr. Cantwell has extensive research and industry experience in cancer immunotherapy drug discovery and development with a special focus on viral cancer immunotherapy. Dr. Cantwell has authored numerous peer-reviewed publications, including articles in the high-impact scientific journals such as Nature Medicine, Nature Communications, and Journal of Clinical Investigation. Dr. Cantwell is an inventor on multiple technologies including MEM-288 which directly targets cancer cells and supercharges the immune system. Dr. Cantwell has a PhD in Biomedical Sciences from the University of California San Diego where he specialized in cancer immunotherapy and gene therapy advancements.

Matthew Collinson-Pautz, PhD
Senior Scientist
Bellicum Pharmaceuticals

Matthew Collinson-Pautz is a Senior Scientist in Translational Research at Bellicum. Joining Bellicum in 2016, Matthew initially worked in the early preclinical discovery group developing novel technologies to enhance the performance of adoptive cell therapies, including CAR-T. From there, he transitioned to the clinical side of drug development, where he currently works on biomarkers for Bellicum’s lead GoCAR-T program, BPX-601, in advanced solid tumors. He received his BA from Augustana College and his PhD in Translational Biology and Molecular Medicine from Baylor College of Medicine.
Patricia Lawman, PhD, co-founder and CEO of Morphogenesis, Inc., received her graduate education in molecular biology and immunology from the College of Medicine at the University of Florida where she served as a Postdoctoral Fellow in Pediatric Hematology and Oncology. Prior to founding Morphogenesis, Dr. Lawman was Division Director of Cancer Molecular Biology at the Walt Disney Memorial Cancer Institute in Orlando, FL, where she initiated and coordinated molecular biology, gene targeting and universal stem cell projects. She has held adjunct faculty positions at the University of Central Florida and the University of South Florida and has served on numerous committees at local/state/federal levels. Dr. Lawman holds over 25 patents and as many publications, and has received multiple honors including 2012 Tampa Bay Business Journal Technology Business Woman of the Year. Under her direction, Morphogenesis has raised over $25M and is about to enter Phase II human clinical trials for its cancer immunotherapy.

Dr. Scholler is a Director in the Translational Medicine department of Kite, a Gilead company where she manages Kite’s External Research Collaborations with academic laboratories to advance the understanding of cellular therapy mechanisms of action and resistance. Previously, Dr. Scholler led the Cancer Immunology group at SRI international, developing novel strategies of cancer immunoprevention and targeted imaging with recombinant antibodies (nanobodies). Prior to SRI, Dr. Scholler was an Assistant Professor at the University of Pennsylvania and her laboratory isolated various recombinant antibodies. Her reagents have been used both as diagnostic assays (biobodies) and for clinically relevant applications, including to target CAR-T cells in collaboration with Carl June’s laboratory. Dr. Scholler was born and educated in Marseille, France, where she obtained an MD and a PhD in Immunology. She has published 60 manuscripts, editorials, and book chapters, as well as 13 granted patents.
COMING SOON
15TH ANNUAL CONFERENCE
BUSINESS OF BIOTECH

Look for our email announcing the 2021 date and Keynote Speaker
To sign up for updates, email: innovation@moffitt.org
OFFICE OF
INNOVATION
AND INDUSTRY
ALLIANCES

Moffitt Cancer Center, a stand-alone institution located in Tampa, Florida, has a major research enterprise dedicated to the prevention and cure of cancer. Moffitt’s interdisciplinary research teams and entrepreneurship culture creates a fertile ground for innovation.

For licensing and research collaboration opportunities call 813-745-6828 or email innovation@moffitt.org